CTOs on the Move

Aurion Biotech

www.aurionbiotech.com

 
With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Arteriocyte, Inc.

Arteriocyte, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GentiBio

GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. With a focused regional strategy and patient oriented approach, the company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people.